Taiwan-developed novel ophthalmic drug enters 2nd clinical trial in U.S.
10/18/2022 10:52 PM
A novel ophthalmic drug developed by Taiwanese scientists using snake venom peptides has entered a second phase of human trials in the United States, according to the National Science and Technology Council (NSTC) on Tuesday.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Society
Repatriated Taiwanese blogger out on bail, barred from leaving Taiwan
05/02/2025 11:13 AM - Business
U.S. dollar down sharply in Taipei trading
05/02/2025 10:15 AM - Society
Taiwan headline news
05/02/2025 10:12 AM - Business
Taiwan shares open higher
05/02/2025 09:11 AM - Politics
Lai meets Japan delegation, calls for closer security, semiconductor ties
05/01/2025 08:48 PM